myelin-basic-protein and Uterine-Cervical-Neoplasms

A double-blind pilot study of 130 female patients was carried out to determine the feasibility and significance of the EM test in the early diagnosis of carcinoma of the female genital organs and breast. Early stages of cervical carcinoma (carcinoma in situ) as well as fibroid adenoma, mastopathy and breast tumors were tested and compared with the results of their manifest forms. Positive results were recorded in 87.5% of the cases of middle-grade to severe epithelial dysplasia (Papanicolaou III and IV) (n = 10) and in 90% of the cases of carcinoma in situ (n = 16). A positive result in 90% of the cases of carcinoma in situ (n = 16). A positive result in 90% of the cases of genital carcinoma was also recorded. In the case of fibroid adenoma (n = 10) and breast tumor (Prechtel I and II) (n = 16), negative results were recorded in 80.8%, whereas in the manifest forms of carcinoma of the breast a positive result of over 95% was shown. As a result of this pilot study, it can be seen that immunological in vitro screening has clinical significance in the early diagnosis of tumors as well as for confirmation of their manifest forms.

Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Erythrocytes; Female; Humans; Immunoelectrophoresis; In Vitro Techniques; Lymphocytes; Lymphokines; Myelin Basic Protein; Precancerous Conditions; Sheep; Time Factors; Uterine Cervical Neoplasms

Lymphocyte sensitivity to encephalitogenic factor (EF) was measured with the macrophage migration inhibition (MMI) test in 60 women with dysplasia or carcinoma in situ of the cervix, in 10 women with invasive cervical carcinoma, and in 20 women with a variety of benign gynaecological conditions. Significant migration inhibition with EF (P less than 0.01) was seen with lymphocytes taken from 7/13 (54%) women with mild and/or moderate dysplasia, from 22/47 (47%) women with severe dysplasia and/or carcinoma in situ, from 6/10 (60%) women with invasive cervical carcinoma and from 3/20 (15%) women with benign gynaecological conditions. Autologous serum was seen to abrogate EF-mediated migration inhibition in 3/4 sensitized women with mild and/or moderate dysplasia, in 5/7 sensitized women with severe dysplasia and/or csrcinoma in situ and in 2/3 sensitized women with invasive cervical carcinoma. Autologous serum from 2 sensitized women with benign gynaecological conditions did not abrogate the response of their lymphocytes to EF.

Topics: Adolescent; Adult; Aged; Blood; Cell Migration Inhibition; Female; Humans; Immunity, Cellular; Macrophages; Middle Aged; Myelin Basic Protein; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms

Sensitization to human myelin basic protein or encephalitogenic factor (EF), and antigen thought to be analogous to different human tumours, can be measured by the macrophage migration inhibition test (MMI). The MMI test was done on one occasion in 51 women with dysplasia and carcinoma in situ of the cervix; 20 women with non-malignant gynaecological conditions served as controls. Sensitization to EF was found in 71 per cent of women with carcinoma in situ and 42 per cent of women with dysplasia. None of the controls showed sensitization. Sensitization could not be related to histological evidence for cellular infiltration within the cervix.

Topics: Adult; Carcinoma in Situ; Cell Migration Inhibition; Cervix Uteri; Female; Humans; Immunity, Cellular; Macrophages; Middle Aged; Myelin Basic Protein; Precancerous Conditions; Uterine Cervical Neoplasms